We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -0.12% | 32.77 | 32.74 | 33.00 | 33.03 | 32.73 | 33.00 | 1,281,689 | 21:15:00 |
From Nov 2023 to May 2024
By Mauro Orru
Roche Holding's Xolair antibody received priority review treatment from the Food and Drug Administration after a late-stage study yielded positive results that the company said could make Xolair the first medicine to reduce allergic reactions to multiple foods.
The Swiss pharmaceutical company said Tuesday that the FDA should make a decision on approval in the first quarter of the new year, after positive results from a phase 3 study assessing Xolair in patients allergic to peanuts and at least two other common foods.
"Despite the significant and growing health burden from food allergies, treatment advances have been limited," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development. "The FDA's priority review designation acknowledges the unmet need for these patients, and we hope to make Xolair available to as many people as possible living with food allergies in the U.S."
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
December 19, 2023 10:12 ET (15:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
